drugset / Trial / NCT05039177
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
* To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies. * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other cancer therapies. * To evaluate the antitumor activity of ERAS-007 in combination with other cancer therapies. * To evaluate the PK profiles of ERAS-007 and other cancer therapies when administered in combination.
Timeline
- Start
- 2021-09-20
- Primary completion
- 2025-08-15
- Completion
- 2026-01-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | — | Intravenous |
| Subject | ERAS-007 | Unknown | — | Oral |
| Subject | Encorafenib | Small molecule | — | Oral |
| Subject | Palbociclib | Small molecule | — | Oral |